Gelatin and collagen peptide expert Gelita has announced its attendance to BIO International 2025.
Held in Boston from June 16–19, the company will highlight its range of excipients for pharmaceutical formulations, including MEDELLAPRO and VACCIPRO.
Gelatin-derived MEDELLAPRO and collagen peptide-based VACCIPRO are designed to address the requirements of pharmaceutical and medical applications.
They can be used as vaccine stabilisers, while also having applications in tissue engineering, 3D bioprinting, implants and advanced wound care.
MEDELLAPRO also helps with endotoxin control, ensuring product safety and patient wellbeing; being suitable for surgical sealants, hemostatic agents, scaffolds, 3D bioprinting and drug delivery systems.
According to Gelita, vaccines stabilised with VACCIPRO show very low allergenic potential, high bioavailability and excellent cell tissue affinity.
With a strong commitment to quality and innovation, Gelita continues to empower the pharmaceutical and medical device industries with solutions that drive efficiency and safety in the development of life-saving therapies.
Gelita is well advanced in developing biotechnological processes to produce animal-free alternatives with optimised properties that are even more resource-efficient and sustainable than conventional methods.
With the pharmaceutical know-how of the Gelita Pharma Institute and Gelita's Biotech R&D Hub, the company is well-equipped to expand its biotechnological expertise and product portfolio.
Gelita can be found at booth 2865-01 in the German Pavillion, where the team will be on hand to discuss the applications of both MEDELLAPRO and VACCIPRO.
